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Introduction
Community-acquired pneumonia (CAP) is a
common and potentially serious infection that is responsible
for a significant number of outpatient visits and hospital
admissions each year.1,2 Despite effective anti-microbial
therapy, it is responsible for considerable mortality; ranging
from 6.7 to 18 percent in the United Kingdom, and from 6
to 24 percent in the United States.3
A considerable seasonal and geographical difference
in the type and frequency of organisms that cause CAP has
been reported.2 In most studies, S. pneumoniae has been the
most common etiologic agent identified. However,
increasingly, atypical organisms such as L. pneumophila, C.
pneumoniae and M. pneumoniae are being reported as
causes for CAP more frequently than was previously
thought.4A large-scale study conducted in the United States
identified atypical pathogens in 60% of cases.5
Available therapeutic guidelines for the empirical
treatment of CAP rely on studies from the Western world.
There is scarcity of information in the local literature about
the prevalence of microbes causing CAP in this part of the
world. The only study done in Pakistan on frequency of
atypical pneumonia used a clinical approach for diagnosis
in hospitalised children which is not reliable in terms of
differentiating between etiologic causes of pneumonia.6
We conducted this study to determine the frequency
of microbial causes of CAP and to provide background data
to assist the development of antibiotic therapies for local use.
Patients and Methods
The descriptive study was conducted prospectively
from February 2007 to March 2008. All consenting adult
patients (age 16 and above), presenting consecutively to the
Aga Khan University Hospital, Karachi, with a CAP
diagnosis were enrolled in the study. CAP was defined as
the presence of at least two symptoms of lower respiratory
tract infection, accompanied by acute infiltrate on chest
radiograph or auscultatory findings of consolidation on
chest examination.7 Patients were excluded if they had been
transferred from some other hospital, or those who
developed symptoms while already hospitalised, or patients
with a suspicion of post-obstructive pneumonia and
immuno-compromised hosts. 
Written informed consent was obtained from all
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Abstract
Objective: To determine the frequency of community-acquired respiratory pathogens with special focus on
atypical organisms in patients presenting to a tertiary care facility with community-acquired pneumonia (CAP).
Methods: The descriptive study on adult patients was conducted from February 2007 to March 2008 at the Aga
Khan University Hospital, Karachi. It comprised 124 consenting patients of age 16 and above who presentd with
a diagnosis of community-acquired pneumonia. The diagnostic modalities used were based on significant
changes in antibody titer or persisting high antibody titers in the case of Mycoplasma pneumoniae and
Chalmydia pneumoniae infections, or bacterial antigen in urine, in the case of Legionella pneumophila serogroup
1 infection. Pyogenic bacteria were identified on the results of respiratory secretions or blood cultures.
Continuous data and categorical variables were worked out using SPSS version 15.
Results: Among the 124 patients enrolled, an etiologic agent was identified in 44 (35.4%) patients. The most
common organism was Mycoplasma pneumoniae (n=21, 17%), followed by Chlamydia pneumoniae (n=15,
12%), Streptococcus pneumoniae (n=9, 7%), Haemophilus influenzae (n=2, 1.6%), Klebsiella pneumoniae (n=2,
1.6%) and Staphylococcus aureus (n=1, 0.8%). Streptococcus pneumoniae was the most common organism
isolated from blood cultures. No cases of Legionella pneumophila serogroup 1 were identified.
Conclusions: Mycoplasma pneumoniae and Chalmydia pneumoniae are significant etiologic agents for
community-acquired pneumonia occurring in Karachi. Local treatment guidelines for community-acquired
pneumonia should include therapy directed specifically at these agents. 
Original Article
patients, and the study was approved by the Ethical Review
Committee (ERC) of the Aga Khan University. A structured
data sheet was used to collect clinical and laboratory data.
Results of routine investigations such as complete blood
count, serum electrolytes, blood urea nitrogen, creatinine
and arterial blood gases were recorded. Patients were
assessed for severity of disease using the British Thoracic
Society (BTS) guidelines.7 Blood cultures were collected in
Bactec aerobic and anaerobic bottles (Beckton Dickinson,
USA).[8] Sputum examination included Gram stain, culture
and sensitivity and Ziehl- Neelsen stain if Mycobacterium
tuberculosis was suspected. Serum samples were obtained
within 24 hours of admission for serologic testing of M.
pneumoniae and C. pneumoniae. Convalescent serum
sample was obtained at the follow-up visit. The mean
interval between two samples was 14 days. For the
detection of urinary antigen of L. pneumophila serogroup 1,
immuno-chromatographic assay (NOW-BINAX, Inverness
medical professional diagnostics) was used. The infection
due to C. pneumoniae was determined by enzyme linked
immunosorbant assay (ELISA) using a commercial Nova
Tec (Dietzenbach, Germany). Using this method, serum
antibody titer of immunoglobulin M (IgM) was measured. A
four-fold or greater increase in titer between paired samples
or a cutoff value of 11 NTU (Novatec unit) or above was
considered positive. For M. pneumoniae, EIA (enzyme
immuno-assay) Serodia-MycoII, Fujirebio Inc. (Tokyo,
Japan) was used. A titer of 1:80 or above in at least one
serum sample or four-fold increase in antibodies between
the paired serum sample was considered positive. 
Results were worked out as mean ± SD for continuous
data and as frequency (percentage) for categorical variables.
All analyses were conducted by using the Statistical Package
For Social Sciences (SPSS), version 15.0. 
Results
Among the study population of 124, the mean age
was 56.5 ± 19.5 years (range 16-90 years), while 69
(55.6%) were male. Three (2.4%) were treated as
outpatients, while 121 (97%) patients were admitted. Of
the total, 93 (75%) were non-smokers, 27 (21.8%) were ex-
smokers, while 3 (2.4%) were current smokers with a mean
exposure of 22 ± 20 pack years. One patient had a history
of alcohol abuse. Besides, 22 (18%) patients gave a history
of travel; 9 (7%) had travelled internationally to the
western hemisphere, while 6 (5%) had travelled to the rural
areas in Sindh. None of the patients gave a history of
exposure to domestic pets (rabbits, birds) or wildlife
(squirrels, ducks). Also, 74 (59%) patients had underlying
diseases in addition to pneumonia (Table-1).
With respect to presentation, 124 (92%) patients
presented with fever, 107 (86%) cough, 55 (44%) chest pain
and 23 (19%) with altered mental status. The mean duration
of symptom prior to presentation was 8 ±6.3 days.
Admission serum WBC counts ranged from 3 to 60,000
cells, with mean (Confusion-Urea-Respiratory Rate-BP)
CURB-65 score of 1.5 (range 1-4); 73 (60%) patients had
consolidation on chest X rays; with para-pneumonic
effusions developing in 44 (36%) patients and cavitation in
7 (6%). Bilateral interstitial infiltrates were present in 49
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Table-1: Characteristics of the study population (n=124).
Characteristic n %
Mean age, range (years) 56.5±19.5 16-90
Age group (years)
16 – 44 30 24
45 – 64 46 37
65 and above 48 39
Gender
Male 69 56
Female 55 44
CURB-65
0 40 32
1 24 19
2 38 31
3 17 13.6
4 3 2
5 2 1.6
Smoking Status
Current smokers 4 2.4
Ex-smokers (>6 months) 27 21.8
Never smokers 93 75
Co morbid illnesses
Asthma /Chronic Obstructive Pulmonary
Disease (COPD) 23 18
Bronchiectasis 1 0.8
Pulmonary fibrosis 1 0.8
Hypertension 39 31
Congestive heart failure (CHF) 2 1.6
Ischaemic heart disease (IHD) 25 20
Diabetes mellitus (DM) 23 18
Chronic kidney disease (CKD) 8 6
Chronic liver disease (CLD) 6 4
Treated Tuberculosis (TB) 5 4
None 30 24
Antibiotics taken prior to hospital admission 26 21
CURB-65: Confusion-Urea-Respiratory Rate-BP-Age <65.
Table-2: Etiologic agents of community-acquired pneumonia
identified by culture and serological testing.
Organism identified 52 (42%)
By Serology:
Mycoplasma pneumoniae 21 (17%)
Chlamydia pneumonia 15 (12%)
By Culture:
Streptococcus pneumoniae 9 (7%)
Haemophilus influenzae 2 (2%)
Klebsiella pneumoniae 2 (2%)
Mycobacterium tuberculosis 2 (2%)
Staphylococcus aureus 1 (0.8%)
No organism identified 72 (58%)
(40%) patients. There was no correlation found between
radiological presentation and etiological organism. 
Of the patients 6 (21%) had received multiple
antibiotics prior to hospitalisation and 6 (5%) were started
empirically on anti-tuberculous therapy; 2 of these
subsequently had microbiological confirmation of M.
tuberculosis. Besides, 49 (7%) patients had been
hospitalised for CAP in the preceding year.
Among the 124 patients, an etiologic agent was
identified in 52 (41.93%). Atypical pathogens were
identified in 36 (29%) cases of CAP (Table-2). 
All microbial isolates demonstrated sensitivity to
macrolides, with only 80% isolates sensitive to
fluoroqinolones and 86% sensitive to beta-lactam agents.
Complications occurred in 18 (14%) patients; 6
(4.8%) developed respiratory failure; 6 (4.8%) septic shock;
4 (3%) empyema; and 2 (1.6%) pneumothorax. Only 5 (4%)
patients with CAP died, and of these deaths 2 were due to
respiratory failure and 3 from septic shock (Table-3). The
majority (n=119; 96%) of patients were successfully
discharged, with the average length of hospitalisation being
5 ± 3.3 days (range 1-22).
Discussion
The results of the study indicated a predominance of
atypical organisms - M. pneumoniae and C. pneumoniae - as
etiological agents of mild to moderate CAP requiring
hospitalisation. The atypical pathogens causing pneumonias
include C. pneumoniae, M. pneumoniae and L. pneumophila;
and multiple viruses. Atypical pneumonias were previously
regarded as clinically or radiologically distinctive but are now
accepted as being no different in their presentations from
bacterial causes of the usual CAP. Most atypical pathogens
are difficult to isolate and a definitive laboratory diagnosis is
based on serological methods like direct fluorescent antibody
(DFA) and indirect fluorescent antibody (IFA) detection
methods. The morbidity and mortality from CAP can be
considerable. A study from Pakistan reported an 11% crude
mortality rate on 329 patients hospitalised with CAP.9
Treatment protocols for CAP as a matter of routine now
favour the empiric use of agents against atypical
pathogens.10,11 The added costs of care associated with dual
antibiotic therapy (beta-lactams and macrolides) or the more
expensive fluoroqinolones and the possibility of inducing
resistant strains against anti-bacterials which are also
important anti-mycobacterial agents is of special concern to
resource-poor, developing countries. 
We were unable to find any reports on the
prevalence of atypical causes of CAP in adults from
Pakistan. The review of the prevalence of atypical CAP
from the developing world revealed two studies from India
in which the prevalence of M. pneumoniae and L.
pneumophila was reported to be 35% and 27.43%
respectively.12,13 Studies from Jordan14 and Egypt15
reported that 38% to 40% of CAP cases were due to
atypical organisms. The atypical organisms were present in
8 to 25.5% cases cited by studies in Thailand,16 Japan17 and
South Korea.18 Other studies18,19 have also reported 8 to
25.5% CAP cases being due to atypical organisms. Our
results are comparable. We found a prevalence of 29%
cases due to atypical organisms.
Most studies have reported a greater proportion of
patients infected with C. pneumoniae followed by M.
pneumoniae.14,15,19 In contrast, our results identified M.
pneumoniae as the leading cause of CAP (17%) followed by
C. pneumoniae (12%). These proportions are similar to two
studies reporting 12-14% cases due to Mycoplasma and 4%
due to Chlamydia.20,21 This disparity is possibly due to
differences in age and severity of pneumonia between the
groups. We identified no patients with L. pneumoniae
serogroup 1 infection. 
An interesting finding in our study was that only 9
samples were positive for Streptococcus pneumoniae. This
organism has historically been the most common etiologic
cause of CAP in adult patients. S. pneumoniae tends to be
isolated more frequently from patients with severe CAP,
older patients or in patients requiring hospitalisation. Our
patients tended to be younger and had mild to moderate
severity of disease as scored by the CURB-65 scoring
system. Additionally, 21% of patients had previously
received antibiotics which can lead to false negative
cultures. All these may be factors that influenced our low
culture rates.
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Table-3: Age, CURB-65 score and etiologic agent of those patients who died.
Age in years CURB-65 score Organism Cause of death
85 5 Mycoplasma pneumoniae Respiratory failure
81 5 Pseudomonas aeruginosa Septic shock
75 4 Chlamydia pneumoniae Respiratory failure
60 4 None identified Septic shock
38 4 None identified Septic shock
CURB-65: Confusion-Urea-Respiratory Rate-BP-Age <65.
Our results are limited by the large number of
patients in whom both cultures and serological testing failed
to identify an etiologic organism. Researchers from other
developing countries have also reported similar numbers;
some15,17 were unable to isolate any organism in 50-57.1%
cases. Another limitation of our study is that this was a
single-centre study from a large urban hospital and the
results may not be nationally representative.
Conclusion
The results indicate that atypical pathogens play a
larger role in the etiology of mild to moderate CAP than was
previously considered. The study suggests that local
guidelines be modified to include anti-microbial coverage
specifically targeting Chlamydia and Mycoplasma, with
less concern for Legionella.
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